资讯
Asgard Therapeutics has appointed Shane Olwill as Chief Development Officer Asgard Therapeutics, a privately held biotech ...
AviadoBio has launched its phase 1/2 Aspire-FTD trial in the UK, assessing AVB-101, a gene therapy targeting frontotemporal ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果